Clinical, laboratory, molecular, and treatment characteristics and outcome of 28 patients with advSM, stratified by KIT D816V EAB reduction at month 6 (≥25% vs <25%)
Variables . | All patients . | Decrease of KIT D816V . | P* . | |
---|---|---|---|---|
EAB ≥25% . | EAB <25% . | |||
No. of patients (n) | 28 | 17 | 11 | |
Age in y, median (range) | 65 (48-76) | 68 (48-76) | 63 (55-75) | NS |
Males, n (%) | 19 (68) | 10 (59) | 9 (82) | NS |
Diagnosis | ||||
ASM, n (%) | 3 (11) | 3 (18) | 0 | |
MCL, n (%) | 2 (7) | 2 (12) | 0 | |
SM-AHN | 23 (82) | 12 (71) | 11 (100) | NS |
SM, n (%) | 19 (83) | 10 (83) | 9 (82) | |
MCL, n (%) | 4 (17) | 2 (17) | 2 (18) | |
Any response according Valent criteria | 15 (54) | 13 (76) | 2 (18) | .006 |
Molecular profile | ||||
S/A/Rpos, n (%) | 18 (65) | 9 (53) | 9 (82) | NS |
Other mutation, n (%) | 6 (21) | 4 (24) | 2 (18) | |
No mutation, n (%) | 4 (14) | 4 (24) | 0 | |
Loss of KIT response†, n (%) | 4 (24) | — | ||
S/A/Rpos, n (%) | 4 (24) | — | ||
Median time on midostaurin, mo (range) | 19 (6-88) | 25 (6-88) | 9 (7-35) | .01 |
Number of patients on midostaurin at time of reporting, n (%) | 10 (36) | 10 (59) | 0 | .002 |
Outcome | ||||
Median OS, mo (95% CI) | 45 (17-73) | NR | 27 (7-51) | .0004‡ |
Death, n (%) | 14 (50) | 4 (24) | 10 (91) |
Variables . | All patients . | Decrease of KIT D816V . | P* . | |
---|---|---|---|---|
EAB ≥25% . | EAB <25% . | |||
No. of patients (n) | 28 | 17 | 11 | |
Age in y, median (range) | 65 (48-76) | 68 (48-76) | 63 (55-75) | NS |
Males, n (%) | 19 (68) | 10 (59) | 9 (82) | NS |
Diagnosis | ||||
ASM, n (%) | 3 (11) | 3 (18) | 0 | |
MCL, n (%) | 2 (7) | 2 (12) | 0 | |
SM-AHN | 23 (82) | 12 (71) | 11 (100) | NS |
SM, n (%) | 19 (83) | 10 (83) | 9 (82) | |
MCL, n (%) | 4 (17) | 2 (17) | 2 (18) | |
Any response according Valent criteria | 15 (54) | 13 (76) | 2 (18) | .006 |
Molecular profile | ||||
S/A/Rpos, n (%) | 18 (65) | 9 (53) | 9 (82) | NS |
Other mutation, n (%) | 6 (21) | 4 (24) | 2 (18) | |
No mutation, n (%) | 4 (14) | 4 (24) | 0 | |
Loss of KIT response†, n (%) | 4 (24) | — | ||
S/A/Rpos, n (%) | 4 (24) | — | ||
Median time on midostaurin, mo (range) | 19 (6-88) | 25 (6-88) | 9 (7-35) | .01 |
Number of patients on midostaurin at time of reporting, n (%) | 10 (36) | 10 (59) | 0 | .002 |
Outcome | ||||
Median OS, mo (95% CI) | 45 (17-73) | NR | 27 (7-51) | .0004‡ |
Death, n (%) | 14 (50) | 4 (24) | 10 (91) |